PCEP enhances IgA mucosal immune responses in mice following different immunization routes with influenza virus antigens

Journal of Immune Based Therapies and Vaccines

Volumn 8, Issue , 2010, Pages

  Eng, Nelson F ^a   Garlapati, Srinivas ^a   Gerdts, Volker ^a   Babiuk, Lorne A ^b   Mutwiri, George K ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G2A; INFLUENZA VACCINE; POLY[DI(SODIUMCARBOXYLATOETHYLPHENOXY)PHOSPHAZENE]; POLYMER; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CYTOKINE PRODUCTION; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; IMMUNE RESPONSE; IMMUNITY; INFLUENZA VIRUS; MOUSE; MOUSE STRAIN; MUCOSA; NONHUMAN; SPLEEN CELL;

EID: 77955809145     PISSN: None     EISSN: 14768518     Source Type: Journal    
DOI: 10.1186/1476-8518-8-4     Document Type: Article

References (47)

1. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005, 11:S45-S53. 10.1038/nm1213, 15812489.
2. Hodge LM, Marinaro M, Jones HP, McGhee JR, Kiyono H, Simecka JW. Immunoglobulin A (IgA) responses and IgE-associated inflammation along the respiratory tract after mucosal but not systemic immunization. Infect Immun 2001, 69:2328-2338. 10.1128/IAI.69.4.2328-2338.2001, 98162, 11254590.
3. van Ginkel FW, Jackson RJ, Yoshino N, Hagiwara Y, Metzger DJ, Connell TD, Vu HL, Martin M, Fujihashi K, McGhee JR. Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract. Infect Immun 2005, 73:6892-6902. 10.1128/IAI.73.10.6892-6902.2005, 1230900, 16177369.
4. Mutwiri G, van Drunen Littel-van den H, Babiuk LA. Approaches to enhancing immune responses stimulated by CpG oligodeoxynucleotides. Adv Drug Deliv Rev 2009, 61:226-232. 10.1016/j.addr.2008.12.004, 19162103.
5. Payne LG, Jenkins SA, Woods AL, Grund EM, Geribo WE, Loebelenz JR, Andrianov AK, Roberts BE. Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine. Vaccine 1998, 16:92-98. 10.1016/S0264-410X(97)00149-7, 9607015.
6. Payne LG, Van NG, Barchfeld GL, Siber GR, Gupta RK, Jenkins SA. PCPP as a parenteral adjuvant for diverse antigens. Dev Biol Stand 1998, 92:79-87.
7. McNeal MM, Rae MN, Ward RL. Effects of different adjuvants on rotavirus antibody responses and protection in mice following intramuscular immunization with inactivated rotavirus. Vaccine 1999, 17:1573-1580. 10.1016/S0264-410X(98)00359-4, 10195795.
8. Wu JY, Wade WF, Taylor RK. Evaluation of cholera vaccines formulated with toxin-coregulated pilin peptide plus polymer adjuvant in mice. Infect Immun 2001, 69:7695-7702. 10.1128/IAI.69.12.7695-7702.2001, 98864, 11705950.
9. Andrianov AK, Payne LG. Polymeric carriers for oral uptake of microparticulates. Adv Drug Deliv Rev 1998, 34:155-170. 10.1016/S0169-409X(98)00038-6, 10837676.
10. Lu Y, Salvato MS, Pauza CD, Li J, Sodroski J, Manson K, Wyand M, Letvin N, Jenkins S, Touzjian N, et al. Utility of SHIV for testing HIV-1 vaccine candidates in macaques. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 12:99-106.
11. Payne LG, Van Nest G, Barchfeld GL, Siber GR, Gupta RK, Jenkins SA. The utility of PCPP as a parenteral adjuvant for diverse antigens. Modulation of the Immune Response to Vaccine Antigens 1997, Geneva: International Association of Biological Standardization, Haaheim L.
12. Mapletoft JW, Oumouna M, Kovacs-Nolan J, Latimer L, Mutwiri G, Babiuk LA, van Drunen Littel-van den Hurk S. Intranasal immunization of mice with a formalin-inactivated bovine respiratory syncytial virus vaccine co-formulated with CpG oligodeoxynucleotides and polyphosphazenes results in enhanced protection. J Gen Virology 2008, 89:250-260.
13. Mutwiri G, Benjamin P, Soita H, Townsend H, Yost R, Roberts B, Andrianov AK, Babiuk LA. Poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP) is a potent enhancer of mixed Th1/Th2 immune responses in mice immunized with influenza virus antigens. Vaccine 2007, 25:1204-1213. 10.1016/j.vaccine.2006.10.011, 17140708.
14. Mutwiri GK, Babiuk LA. Potential of polyphosphazenes in modulating vaccine-induced immune responses II: Investigations in large animals. Polyphosphazenes for Biomedical applications 2009, 77-84. Toronto: John Wiley & Sons, Andrianov AK.
15. Eng NF, Garlapati S, Lai K, Gerdts V, Mutwiri GK. Polyphosphazenes enhance mucosal and systemic immune responses in mice immunized intranasally with influenza antigens. The Open Vaccine Journal 2009, 2:134-143.
16. Andrianov AK, Sargent JR, Sule SS, LeGolvan MP, Woods AL, Jenkins SA, Payne LG. Synthesis, physico-chemical properties and immunoadjuvant activity of water-soluble phosphazene polyacids. J Bioact and Compat Polymers 1998, 13:243-256.
17. Andrianov AK, Svirkin YY, LeGolvan MP. Synthesis and biologically relevant properties of polyphosphazene polyacids. Biomacromolecules 2004, 5:1999-2006. 10.1021/bm049745d, 15360316.
18. Mutwiri G, Benjamin P, Soita H, Babiuk LA. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen. Vaccine 2008, 26:2680-2688. 10.1016/j.vaccine.2008.03.031, 18430493.
19. Payne LG, Jenkins SA, Andrianov A, Roberts BE. Water-soluble phosphazene polymers for parenteral and mucosal vaccine delivery. Pharm Biotechnol 1995, 6:473-493.
20. Andrianov AK, Decollibus DP, Gillis HA, Kha HH, Marin A. Polyphosphazene immunoadjuvants for intradermal vaccine delivery. Polyphosphazenes for biomedical applications 2009, 101-116. Hoboken, NJ: John Wiley & Sons.
21. Andrianov AK, Decollibus DP, Gillis HA, Kha HH, Marin A, Prausnitz MR, Babiuk LA, Townsend H, Mutwiri G. Poly[di(carboxylatophenoxy)phosphazene] is a potent adjuvant for intradermal immunization. Proc Natl Acad Sci USA 2009, 106:18936-18941. 10.1073/pnas.0908842106, 2770009, 19864632.
22. Tamura S, Iwasaki T, Thompson AH, Asanuma H, Chen Z, Suzuki Y, Aizawa C, Kurata T. Antibody-forming cells in the nasal-associated lymphoid tissue during primary influenza virus infection. J Gen Virol 1998, 79(Pt 2):291-299.
23. Renegar KB, Small PA. Immunoglobulin A mediation of murine nasal anti-influenza virus immunity. J Virol 1991, 65:2146-2148. 240095, 2002558.
24. Asanuma H, Koide F, Suzuki Y, Nagamine T, Aizawa C, Kurata T, Tamura S. Cross-protection against influenza virus infection in mice vaccinated by combined nasal/subcutaneous administration. Vaccine 1995, 13:3-5. 10.1016/0264-410X(95)80002-U, 7762274.
25. Hirabayashi Y, Kurata H, Funato H, Nagamine T, Aizawa C, Tamura S, Shimada K, Kurata T. Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination. Vaccine 1990, 8:243-248. 10.1016/0264-410X(90)90053-O, 2363302.
26. Tamura S, Samegai Y, Kurata H, Nagamine T, Aizawa C, Kurata T. Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit. Vaccine 1988, 6:409-413. 10.1016/0264-410X(88)90140-5, 2848377.
27. Tamura S, Ito Y, Asanuma H, Hirabayashi Y, Suzuki Y, Nagamine T, Aizawa C, Kurata T. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. J Immunol 1992, 149:981-988.
28. Tamura S, Asanuma H, Ito Y, Yoshizawa K, Nagamine T, Aizawa C, Kurata T. Formulation of inactivated influenza vaccines for providing effective cross-protection by intranasal vaccination in mice. Vaccine 1994, 12:310-316. 10.1016/0264-410X(94)90094-9, 8178552.
29. Tamura SI, Asanuma H, Ito Y, Hirabayashi Y, Suzuki Y, Nagamine T, Aizawa C, Kurata T, Oya A. Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine. Eur J Immunol 1992, 22:477-481. 10.1002/eji.1830220228, 1537382.
30. Watanabe I, Hagiwara Y, Kadowaki SE, Yoshikawa T, Komase K, Aizawa C, Kiyono H, Takeda Y, McGhee JR, Chiba J, et al. Characterization of protective immune responses induced by nasal influenza vaccine containing mutant cholera toxin as a safe adjuvant (CT112K). Vaccine 2002, 20:3443-3455. 10.1016/S0264-410X(02)00351-1, 12297389.
31. de HA, Geerligs HJ, Huchshorn JP, van Scharrenburg GJ, Palache AM, Wilschut J. Mucosal immunoadjuvant activity of liposomes: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes. Vaccine 1995, 13:155-162. 10.1016/0264-410X(95)93129-W, 7625109.
32. Haan L, Verweij WR, Holtrop M, Brands R, van Scharrenburg GJ, Palache AM, Agsteribbe E, Wilschut J. Nasal or intramuscular immunization of mice with influenza subunit antigen and the B subunit of Escherichia coli heat-labile toxin induces IgA- or IgG-mediated protective mucosal immunity. Vaccine 2001, 19:2898-2907. 10.1016/S0264-410X(00)00556-9, 11282201.
33. Atmar RL, Keitel WA, Cate TR, Munoz FM, Ruben F, Couch RB. A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults. Vaccine 2007, 25:5367-5373. 10.1016/j.vaccine.2007.05.002, 2063441, 17559990.
34. Muszkat M, Yehuda AB, Schein MH, Friedlander Y, Naveh P, Greenbaum E, Schlesinger M, Levy R, Zakay-Rones Z, Friedman G. Local and systemic immune response in community-dwelling elderly after intranasal or intramuscular immunization with inactivated influenza vaccine. J Med Virol 2000, 61:100-106. 10.1002/(SICI)1096-9071(200005)61:1<100::AID-JMV16>3.0.CO;2-5, 10745240.
35. Kutteh WH, Hatch KD, Blackwell RE, Mestecky J. Secretory immune system of the female reproductive tract: I. Immunoglobulin and secretory component-containing cells. Obstet Gynecol 1988, 71:56-60.
36. Mitchell LA, Galun E. Rectal immunization of mice with hepatitis A vaccine induces stronger systemic and local immune responses than parenteral immunization. Vaccine 2003, 21:1527-1538. 10.1016/S0264-410X(02)00699-0, 12615450.
37. Lagranderie M, Balazuc AM, Abolhassani M, Chavarot P, Nahori MA, Thouron F, Milon G, Marchal G. Development of mixed Th1/Th2 type immune response and protection against Mycobacterium tuberculosis after rectal or subcutaneous immunization of newborn and adult mice with Mycobacterium bovis BCG. Scand J Immunol 2002, 55:293-303. 10.1046/j.1365-3083.2002.01049.x, 11940236.
38. Lovgren K. The serum antibody response distributed in subclasses and isotypes after intranasal and subcutaneous immunization with influenza virus immunostimulating complexes. Scand J Immunol 1988, 27:241-245. 10.1111/j.1365-3083.1988.tb02343.x, 3340827.
39. Aguila A, Donachie AM, Peyre M, McSharry CP, Sesardic D, Mowat AM. Induction of protective and mucosal immunity against diphtheria by a immune stimulating complex (ISCOMS) based vaccine. Vaccine 2006, 24:5201-5210. 10.1016/j.vaccine.2006.03.081, 16650917.
40. Nygren E, Holmgren J, Attridge SR. Murine antibody responses following systemic or mucosal immunization with viable or inactivated Vibrio cholerae. Vaccine 2008, 26:6784-6790. 10.1016/j.vaccine.2008.10.011, 18951939.
41. Gutierro I, Hernandez RM, Igartua M, Gascon AR, Pedraz JL. Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. Vaccine 2002, 21:67-77. 10.1016/S0264-410X(02)00435-8, 12443664.
42. Hazebrouck S, Przybylski-Nicaise L, Ah-Leung S, del-Patient K, Corthier G, Langella P, Wal JM. Influence of the route of administration on immunomodulatory properties of bovine beta-lactoglobulin-producing Lactobacillus casei. Vaccine 2009, 27:5800-5805. 10.1016/j.vaccine.2009.07.064, 19654068.
43. Russell-Jones GJ. Oral vaccine delivery. J Control Release 2000, 65:49-54. 10.1016/S0168-3659(99)00231-X, 10699269.
44. Kaiserlian D, Etchart N. Epicutaneous and transcutaneous immunization using DNA or proteins. Eur J Dermatol 1999, 9:169-176.
45. Bouveret Le Cam NN, Ronco L, Francon A, Blondeau C, Fanget B. Adjuvants for influenza vaccine. Res Immunol 1998, 149:19-23.
46. Gilbert PB, Chiu YL, Allen M, Lawrence DN, Chapdu C, Israel H, Holman D, Keefer MC, Wolff M, Frey SE. Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials. Vaccine 2003, 21:2933-2947. 10.1016/S0264-410X(03)00158-0, 12798637.
47. Barackman JD, Ott G, O'Hagan DT. Intranasal immunization of mice with influenza vaccine in combination with the adjuvant LT-R72 induces potent mucosal and serum immunity which is stronger than that with traditional intramuscular immunization. Infect Immun 1999, 67:4276-4279. 96738, 10417205.